Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:PFE

Pfizer Inc (PFE)

26.17
+0.57 (2.23%)
as of Jun 11, 2026, 8:00:00 pm Market Open.
322 watching
0
DON'T BUY
Concerned with risk from generic competition to the big pharmas. Prefers Teva (TEVA-Q). The big pharmas will continue to struggle because of this.
DON'T BUY
Lost its ability to grow because of its size. Lipitor represents 20% and it goes off patent next year so they’ll be competing with generics.
PAST TOP PICK
(Top Pick Nov 16/09, Down 5%) Drug stocks have been out of favour. Drug stocks bottomed earlier this year. Have a number of drugs coming off patent. Dividend investors have identified drug companies as targets.
BUY
(Top Pick Nov 30/09, Down 4.77%) $28.23 model price. 64% upside. He keeps on buying it. Held for 4 years in his fund. There is value there and major consolidation going on there. It’s a changing landscape – they are getting together with generics.
DON'T BUY
The whole pharma business is somewhat challenged. They spend lots developing a drug and then a few years later it goes Generic. One drug is a quarter of their business but it goes Generic in 2011. There are better places to go. This is more of a defensive stock. Would prefer a hybrid that just has pharma as a part of the their business.
PAST TOP PICK
(A Top Pick Oct 8/09. Up 5.36%.) Still likes.
HOLD
Has been a long-term sufferer. Product outlook is much better since the merger. They have started to increase their dividend again. This is a dividend stock with some upside potential.
DON'T BUY
(Market Call Minute) Doesn’t buy US stocks.
DON'T BUY
Pharma model, i.e. spending a boatload of money developing drugs and getting it into market, is really stumbling. Then the clock starts ticking with generics coming in down the road. Lipitor expires next year.
DON'T BUY
Their big drug Lipitor comes off patent next year, which will be a lot of revenue that will be difficult to replace. Have an “OK” pipeline. Because of their size, it takes a huge blockbuster drug to turn the needle to a positive direction.
HOLD
$2 in annualized earnings. Very cheap stock. Doesn't have the growth that it used to. Have global growth and is a beneficiary of the decline in the US$.
BUY
Like it for its dividend of about 4.1%. Very high cash flow. Have diversified their product line with the acquisition of Wyeth.
BUY ON WEAKNESS
(Market Call Minute) If it came down a little bit be would be much more interested.
DON'T BUY
Great company with a great yield and trading at a very low multiple. Pharmaceutical industry made so much money on their blockbuster drugs but that dried up. This company has made some good acquisitions and are continuing to cut costs. Pipeline is reasonable but you're not going to see the big blockbuster drugs in the next several years.
DON'T BUY
Wouldn't own any US pharmaceutical companies. Research pipeline cupboard is really bare. Doesn't see any growth. A lot of generic competition.
Showing 361 to 375 of 801 entries